financetom
Business
financetom
/
Business
/
PepsiCo to buy prebiotic brand Poppi for nearly $2 billion deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PepsiCo to buy prebiotic brand Poppi for nearly $2 billion deal
Mar 17, 2025 6:46 AM

(Reuters) -PepsiCo said on Monday it would buy prebiotic soda brand Poppi for $1.95 billion, expanding in the "healthier soda" category at a time when the company is battling falling demand for its traditional beverages and snacks.

Young Americans are increasingly turning to healthier sodas and energy drinks as part of a broader shift to fitness and lifestyle products, with rival Coca-Cola expanding its Simply brand to launch a prebiotic soda called "Simply Pop".

Peers such as Celsius Holdings and Keurig Dr Pepper have also snapped up smaller energy and wellness drink makers to build out and expand in the fast-expanding market.

PepsiCo has been struggling to boost demand for its sodas and snacks as customers moved to cheaper private labels after several price hikes.

Meanwhile, prebiotic sodas have become a top-growing category in the U.S. within the carbonated drinks segment, powered by a shift in preference to more health and wellness drinks focused on gut health.

Poppi combines prebiotics, fruit juice, and apple cider vinegar to create a low-calorie soda with no more than five grams of sugar per serving, PepsiCo said.

The Austin, Texas-based company's retail sales jumped 122%, year-over-year, in the 12-weeks through February 22 and now holds about a 1% share of the total carbonated soft drinks category, according to BNP Paribas.

Poppi was founded by Stephen and Allison Ellsworth.

The deal includes $300 million of anticipated cash tax benefits for a net purchase price of $1.65 billion, the company said, without disclosing additional terms of the deal.

(Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Coinbase Q3 EPS beats estimates on higher trading volumes
Coinbase Q3 EPS beats estimates on higher trading volumes
Oct 30, 2025
Overview * EPS for Q3 beats analyst expectations * Net income for Q3 exceeds analyst estimates * Adjusted EBITDA for Q3 beats consensus Outlook * Coinbase expects October transaction revenue to be approximately $385 mln * Subscription and services revenue forecasted at $710-$790 mln for Q4'25 * Technology & development expenses projected at $925-$975 mln for Q4'25 Result Drivers *...
Atlassian Fiscal Q1 Adjusted Earnings, Revenue Rise; Q2 Revenue Guidance Set
Atlassian Fiscal Q1 Adjusted Earnings, Revenue Rise; Q2 Revenue Guidance Set
Oct 30, 2025
04:18 PM EDT, 10/30/2025 (MT Newswires) -- Atlassian ( TEAM ) reported fiscal Q1 adjusted earnings late Thursday of $1.04 per diluted share, up from $0.77 a year earlier. Analysts polled by FactSet expected $0.84. Revenue for the three months ended Sept. 30 was $1.17 billion, up from $970.2 million a year earlier. Analysts surveyed by FactSet expected $1.40 billion....
Stryker Q3 Adjusted Earnings, Net Sales Rise; 2025 Guidance Updated
Stryker Q3 Adjusted Earnings, Net Sales Rise; 2025 Guidance Updated
Oct 30, 2025
04:17 PM EDT, 10/30/2025 (MT Newswires) -- Stryker (SYK) reported Q3 adjusted earnings late Thursday of $3.19 per diluted share, up from $2.87 a year earlier. Analysts polled by FactSet expected $3.13. Net sales in the three months ended Sept. 30 rose to $6.06 billion from $5.49 billion a year earlier. Analysts surveyed by FactSet expected $6.04 billion. The company...
Biotech drug developer Ardelyx's Q3 product revenue rises 15%
Biotech drug developer Ardelyx's Q3 product revenue rises 15%
Oct 30, 2025
Overview * Ardelyx Q3 2025 product revenue grows 15% yr/yr to $105.5 mln * IBSRELA Q3 revenue rises 92% yr/yr to $78.2 mln, guidance raised * XPHOZAH Q3 revenue declines yr/yr due to Medicare coverage changes Outlook * Ardelyx ( ARDX ) raises 2025 IBSRELA revenue guidance to $270-275 mln * Company expects continued growth for XPHOZAH in Q4 2025...
Copyright 2023-2026 - www.financetom.com All Rights Reserved